Why the study?
Do RNA-targeted therapeutics effectively reduce atherogenic lipid levels in patients with lipometabolic disorders?
Do RNA-targeted therapeutics effectively reduce atherogenic lipid levels in patients with lipometabolic disorders?
RNA-targeted therapeutics represent a revolutionary, long-acting approach for the targeted treatment of lipometabolic disorders, including elevated LDL-C, triglycerides, and lipoprotein(a).
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Lüscher et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: